KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) Long-Term Debt Repayments (2017 - 2025)

Historic Long-Term Debt Repayments for Bristol Myers Squibb (BMY) over the last 14 years, with Q3 2025 value amounting to $229.0 million.

  • Bristol Myers Squibb's Long-Term Debt Repayments fell 9075.87% to $229.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year decrease of 3634.31%. This contributed to the annual value of $2.9 billion for FY2024, which is 2593.45% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's Long-Term Debt Repayments stood at $229.0 million, which was down 9075.87% from $2.5 billion recorded in Q3 2024.
  • In the past 5 years, Bristol Myers Squibb's Long-Term Debt Repayments registered a high of $5.8 billion during Q1 2022, and its lowest value of $229.0 million during Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's median Long-Term Debt Repayments value was $1.8 billion (recorded in 2023), while the average stood at $2.0 billion.
  • In the last 5 years, Bristol Myers Squibb's Long-Term Debt Repayments skyrocketed by 45700.0% in 2022 and then tumbled by 9169.27% in 2023.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Long-Term Debt Repayments stood at $500.0 million in 2021, then skyrocketed by 457.0% to $2.8 billion in 2022, then decreased by 28.19% to $2.0 billion in 2023, then rose by 23.9% to $2.5 billion in 2024, then tumbled by 90.76% to $229.0 million in 2025.
  • Its Long-Term Debt Repayments was $229.0 million in Q3 2025, compared to $2.5 billion in Q3 2024 and $395.0 million in Q2 2024.